

## PACIFIC EDGE ANNUAL SHAREHOLDERS MEETING PRESENTATION

**DUNEDIN, New Zealand** – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) is today holding its Annual Shareholders Meeting at LINK Market Services offices in Auckland, commencing at 10.00am.

It attaches presentations given by Chairman Chris Gallaher, Chief Executive Dr Peter Meintjes, President Pacific Edge Diagnostics USA David Levison, and Chief Medical Officer Dr Tamer Aboushwareb.

In the presentation Pacific Edge notes, it expects to manage cash reserves - in the event of an adverse Medicare coverage decision - until it regains coverage, a process it would expect to take around 4 years.

Shareholders and other interested parties can also join the meeting online at:

[www.virtualmeeting.co.nz/peb23](http://www.virtualmeeting.co.nz/peb23)

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

### For more information:

#### Investors:

Dr Peter Meintjes  
Chief Executive  
Pacific Edge  
P: 022 032 1263

#### Media:

Richard Inder  
The Project  
P: +64 21 645 643

## OVERVIEW

**Pacific Edge:** [www.pacificedgedx.com](http://www.pacificedgedx.com)

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

**Cxbladder:** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 4,400 US urologists in the diagnosis and management of more than 100,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all residents have the option of buying the test online.

